Shareholders in 2seventy bio, Inc. ( NASDAQ:TSVT ) had a terrible week, as shares crashed 22% to US$3.92 in the ...

Revenue missed analyst estimates by 7.0%. Earnings per share (EPS) exceeded analyst estimates by 21%. Looking ahead, revenue ...

Biopharma giant Gilead Sciences will shut down its office in Seattle's Eastlake neighborhood, the company confirmed to ...

Seventy Bio, Inc. ( (TSVT) ) has released its Q3 earnings. Here is a breakdown of the information 2Seventy Bio, Inc. presented to its ...

News release. Janssen. February 28, 2022. https://bit.ly/35yWwjv U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s ...

BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.

Inc. (TSVT) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $1 per share a year ago. These figures are adjusted for ...

The company ended the quarter with $192 million in cash and equivalents, enough to fund operations past 2027. 2seventy Bio ...

Senstar Technologies Corporation , a leading international provider of comprehensive physical, video and access control security products and solutions, today announced its financial results for the ...

The latest announcement is out from 2seventy bio ( (TSVT) ). 2seventy bio reported impressive third-quarter results with a 42% increase in ...

Here, the authors describe a non-covalent bio-condensation between biomass DNA and guanosine monophosphate, mimicking chromatin folding and creating an all-nucleic hydrogel as a carrier for both ...

Shares of 2seventy bio were trading at $4.73 as of November 07. Over the last 52-week period, shares are up 107.46%. Given that these returns are generally positive, long-term shareholders should be ...